APA

O'Connor C. M., Leonard D., Wiredja D., Avelar R. A., Wang Z., Schlatzer D., Bryson B., Tokala E., Taylor S. E., Upadhyay A., Sangodkar J., Gingras A., Westermarck J., Xu W., DiFeo A., Brautigan D. L., Haider S., Jackson M. & Narla G. (20200619). Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. : Oncogene.

Chicago

O'Connor Caitlin M, Leonard Daniel, Wiredja Danica, Avelar Rita A, Wang Zhizhi, Schlatzer Daniela, Bryson Benjamin, Tokala Eesha, Taylor Sarah E, Upadhyay Aditya, Sangodkar Jaya, Gingras Anne-Claude, Westermarck Jukka, Xu Wenqing, DiFeo Analisa, Brautigan David L, Haider Shozeb, Jackson Mark and Narla Goutham. 20200619. Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. : Oncogene.

Harvard

O'Connor C. M., Leonard D., Wiredja D., Avelar R. A., Wang Z., Schlatzer D., Bryson B., Tokala E., Taylor S. E., Upadhyay A., Sangodkar J., Gingras A., Westermarck J., Xu W., DiFeo A., Brautigan D. L., Haider S., Jackson M. and Narla G. (20200619). Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. : Oncogene.

MLA

O'Connor Caitlin M, Leonard Daniel, Wiredja Danica, Avelar Rita A, Wang Zhizhi, Schlatzer Daniela, Bryson Benjamin, Tokala Eesha, Taylor Sarah E, Upadhyay Aditya, Sangodkar Jaya, Gingras Anne-Claude, Westermarck Jukka, Xu Wenqing, DiFeo Analisa, Brautigan David L, Haider Shozeb, Jackson Mark and Narla Goutham. Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. : Oncogene. 20200619.